We demonstrated that de novo lipogenesis might cause oxaliplatin resistance in CRC and that inhibiting FASN and lipid synthesis could resensitize oxaliplatin-resistant cell lines by regulating the MAPK/ERK and PI3K/AKT pathways. The gene discussed is AKT1; the disease is colorectal carcinoma.